Natriuretic peptide assays revisited: Do we need pro-B-type natriuretic peptide?

Journal of the American College of Cardiology

Volumn 57, Issue 12, 2011, Pages 1396-1398

  Emdin, Michele ^a   Passino, Claudio ^a,b   Clerico, Aldo ^a,b  

^a FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

biomarker; BNP; heart failure; NT proBNP; proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PRO BRAIN NATRIURETIC PEPTIDE[1-108]; UNCLASSIFIED DRUG;

AUTOMATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HEART LEFT VENTRICLE FAILURE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; NOTE; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

EID: 79952691783     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.09.075     Document Type: Editorial

References (18)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94. (Pubitemid 11184926)
2. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006;290:H17-29.
3. Goetze JP. Biosynthesis of cardiac natriuretic peptides. Results Probl Cell Differ 2010;50:97-120.
4. Seferian KR, Tamm NN, Semenov AG, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866-73. (Pubitemid 46744242)
5. Mogelvang R, Goetze JP, Schnohr P, et al. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol 2007;23;50:1694-701. (Pubitemid 47562682)
6. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8. (Pubitemid 46349497)
7. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;53:e1-90.
8. Emdin M, Fontana M, Poletti R, et al. Natriuretic peptide testing in primary care patients. Clin Chem Lab Med 2008;46:1533-42.
9. Luckenbill KN, Christenson RH, Jaffe AS, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NTproBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008;54:619-21.
10. 1-108 circulates in the general community: plasma determinants and detection of left ventricular systolic dysfunction. J Am Coll Cardiol 2011;57:1386-95.
11. Giuliani I, Rieunier F, Larue C, et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006;52:1054-61. (Pubitemid 43794417)
12. Dries DL, Ky B, Wu AH, Rame JE, Putt ME, Cappola TP. Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. Circ Heart Fail 2010;3:220-7.
13. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem 2004;50:33-50. (Pubitemid 38125697)
14. McGrath MF, de Bold AJ. Determinants of natriuretic peptide gene expression. Peptides 2005;26:933-43. (Pubitemid 40725367)
15. Chen HH. Heart failure: a state of brain natriuretic peptide deficiency or resistance or both! J Am Coll Cardiol 2007;49:1089-91.
16. Forfia PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 2007;49:1079-88. (Pubitemid 46349496)
17. Knappe S, Wu F, Masikat MR, et al. Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem 2003;278:52363-70. (Pubitemid 38035826)
18. Dong N, Chen S, Yang J, et al. Plasma soluble corin in patients with heart failure. Circ Heart Fail 2010;3:207-11.